Loading…
← CockpitCompetitor Analysis › PHN.MI PharmaNutra S.p.A.Open in the cockpit ↗

PharmaNutra S.p.A.PHN.MICompetitor analysis, valuation and peers

Italy · EUR·Health Care›Pharmaceuticals: Other
Momentum leader 83
Mkt cap
$922M
US dollars, full cap
Free float
32%
of shares outstanding
$/day
$1.39M
20-day average traded
Fwd P/E
33.5×
forward earnings
ROIC−WACC
+27.0 pp
WACC 6.4%
Hurdle
-14 pp
Req g minus delivered
Next earnings
114 days
12 Mar 2027
Close · EUR€86.80
1D0.0%
1W+2.0%
1M+22.4%
3M+6.2%
6M+2.2%
YTD+59.9%
1Y+73.2%
ATR %2.8%
52w lowhigh9.5% off high

What PharmaNutra does

Employees: 128

PharmaNutra at a glance

Size PharmaNutra (PHN.MI) is an Italy Health Care company (Pharmaceuticals: Other) with a market value of $922M, the 88th largest of 121 Italy companies the cockpit tracks. Shares closed at €86.80 on 18 Nov 2026.

Performance Over six months the shares gained 2.2%, against -18.4% for the median peer and +3.1% for the Italy market (cap-weighted) — 4th highest of 21 in its peer set.

Growth Revenue grew 16.9% over the last twelve months (peer median +1.8%); the operating margin is 22.1% (peer median 13.4%).

Valuation It trades at 33.5× forward earnings against a peer median of 20.0× (5th most expensive of 16).

Price implies For today's price to make sense, revenue must grow about 5% a year for seven years (Req g). Recent delivered growth is +18%, so the hurdle is -14 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 27.0 points above its cost of capital (6.4% WACC).

Next results Next results expected around 12 Mar 2027 (exchange calendar; dates can move).

Relative performance

809010021 May 202621 Aug 202618 Nov 2026PHN.MI 101Peer median 82
Six months, rebased to 100: PharmaNutra against the median of its 20 peers (local-currency closes).

PharmaNutra financials

Reported figures in EUR; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue€148M€132M€115M€100M€82.7M
Revenue growth—+14%+15%+21%—
Gross profit€98.6M€88.9M€78.2M€61.2M€54.6M
EBITDA€36.2M€32.3M€30.2M€24.9M€23.8M
Net income€23.0M€20.0M€16.6M€12.8M€15.0M
Free cash flow€19.7M€16.4M€16.2M-€1.16M-€8.69M
Capital expenditure€5.31M€3.13M€4.19M€13.2M€23.2M
Total debt€20.0M€20.5M€24.3M€28.0M€17.7M

Quarterly statements and history in the cockpit →

PharmaNutra competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%+20%-20%0%+20%002219APN046060326200075600227528773007912142CRON600488PHM300039BIOG-B6472002562JWEL3001580775PHN.MI6-month return →1-month return →
Up and to the right = strong over both horizons. PharmaNutra is the large dot.

Fundamentals: revenue growth against valuation

-20%0%+20%+40%+60%0×200×400×002219APN046060326200075600227528772142PHMBIOG-B6472JWEL300261PHN.MIRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. PharmaNutra is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%+60%0%20%40%60%APN6032620007560022753007912142CRON600488PHM300039BIOG-B6472JWELPHN.MIGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. PharmaNutra is the large dot.

PharmaNutra competitors and peer comparison

How PharmaNutra compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

PharmaNutra against its 20 peers (data as of 18 Nov 2026)
MeasurePHN.MIPeer medianRank in peer set
1-month return+22.4%-7.3%highest of 21
6-month return+2.2%-18.4%4th highest of 21
Distance from 52-week high-9.5%-39.3%3rd highest of 21
Revenue growth (TTM)+16.9%+1.8%6th highest of 21
Operating margin22.1%13.4%7th highest of 21
Forward P/E33.5×20.0×5th most expensive of 16
Growth the price implies (Req g, 7 yrs)4.7%7.3%8th least demanding of 15
Growth delivered (Del g)+18.5%+14.4%5th highest of 15
Hurdle (Req g minus delivered)-13.7 pp-7.7 pp6th least demanding of 15
ROIC minus cost of capital+27.0 pp+0.8 pp4th highest of 21
EV / EBITDA23.1×17.4×2nd most expensive of 9
Net debt / EBITDA-0.1×-1.5×4th most indebted of 11

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
PharmaNutra PHN.MIItaly$922M+2%+17%22%33.5×4.7%+18.5%
New Journey Health Technology Group Co., Ltd.Class A 002219.SZChina$942M-18%-14%8%182.0×n/an/a
Applied Nutrition APN.LUnited Kingdom$986M+31%+51%25%21.4×24.6%+38.5%
Sihuan Pharmaceutical 0460.HKHong Kong$856M-34%+30%15%8.7×n/an/a
TSI 603262.SSChina$842M-46%+3%14%47.7×24.3%+13.4%
Shandong Xinhua Pharmaceutical 000756.SZChina$1.01B-17%-5%4%20.0×0.5%+7.9%
Guilin Sanjin Pharmaceutical 002275.SZChina$1.05B-12%-3%24%12.8×-8.7%+5.5%
China Shineway Pharmaceutical 2877.HKHong Kong$760M-8%-18%25%7.6×n/an/a
Sirio Pharma 300791.SZChina$759M-6%-9%1%16.2×14.1%+15.6%
HBM 2142.HKHong Kong$1.12B-18%+55%44%11.7×13.1%+62.3%
Cronos CRON.TOCanada$1.17B+24%+55%5%16.2×18.8%+26.7%
Tianjin Tianyao Pharmaceuticals 600488.SSChina$718M-36%-12%3%n/a2.1%-1.3%
Pharma Mar PHM.MCSpain$1.21B-38%+32%19%41.4×10.6%-3.9%
Shanghai Kaibao Pharmaceutical 300039.SZChina$703M-20%-14%22%n/a0.4%+4.8%
BioGaia BIOG-B.STSweden$1.25B-4%+13%28%31.0×1.5%+15.5%
Bora Pharmaceuticals 6472.TWTaiwan$1.25B-2%+7%14%10.8×3.5%+60.2%
Brother Enterprises 002562.SZChina$668M-33%+8%4%n/a4.0%+13.5%
Jamieson Wellness JWEL.TOCanada$1.32B+32%+12%13%20.6×13.5%+15.3%
Shanxi Zhendong Pharmaceutical 300158.SZChina$641M-22%-28%-25%n/an/an/a
CK Life Sciences International (Holdings) 0775.HKHong Kong$613M-30%0%0%n/an/an/a
ABA Chemicals 300261.SZChina$592M-26%-16%-23%405.0×n/an/a

Questions

Which companies are PharmaNutra's closest peers?
The cockpit's peer set: New Journey Health Technology Group Co., Ltd.Class A (002219.SZ), Applied Nutrition (APN.L), Sihuan Pharmaceutical (0460.HK), TSI (603262.SS), Shandong Xinhua Pharmaceutical (000756.SZ), Guilin Sanjin Pharmaceutical (002275.SZ), China Shineway Pharmaceutical (2877.HK), Sirio Pharma (300791.SZ).
Is PharmaNutra expensive compared with its peers?
On forward p/e it trades at 33.5× against a peer median of 20.0×, 5th most expensive of 16 in its peer set. For today's price to make sense, revenue must grow about 5% a year for seven years (Req g). Recent delivered growth is +18%, so the hurdle is -14 pp: the price already allows for a slowdown.
How has PharmaNutra stock performed?
Over six months to 18 Nov 2026 the shares returned +2.2% against -18.4% for the median peer; over one year +73.2%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.